Affiliations 

  • 1 School of Science, Monash University Malaysia Campus, Bandar Sunway, Selangor, Malaysia
  • 2 Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Penang, Malaysia
  • 3 School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
  • 4 Center for Cancer and Stem Cell Research, International Medical University, Kuala Lumpur, Malaysia
  • 5 Department of Chemistry, University of Malaya, Kuala Lumpur, Malaysia
Chem Biol Drug Des, 2018 01;91(1):213-219.
PMID: 28719017 DOI: 10.1111/cbdd.13072

Abstract

Both sirtuin and poly(ADP-ribose)polymerase (PARP) family of enzymes utilize NAD+ as co-substrate. Inhibitors of sirtuins and PARPs are important tools in drug discovery as they are reported to be linked to multiple diseases such as cancer. New potent sirtuin inhibitors (2,4,6-trisubstituted benzimidazole) were discovered from reported PARP inhibitor scaffold. Interestingly, the synthesized compounds have contrasting sirtuin and PARP-1 inhibitory activities. We showed that modification on benzimidazoles may alter their selectivity toward sirtuin or PARP-1 enzymes. This offers an opportunity for further discovery and development of new promising sirtuin inhibitors. Molecular docking studies were carried out to aid the rationalization of these observations. Preliminary antiproliferative studies of selected compounds against nasopharyngeal cancer cells also showed relatively promising results.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.